Clinical Trials at DKTK
The effectiveness and safety of new active substances, biomarkers, treatment and diagnostic approaches are first tested in a preclinical phase on cell cultures and animal models. Within the DKTK, special mouse and cell culture systems are being developed that produce results that can be transferred to the human immune system. The effectiveness, dosage and safety of the new treatment and diagnostic concepts are then checked in clinical trials lasting months or years. Promising approaches are then developed further in the laboratory and optimised before going through further clinical control phases. The research focus within the DKTK is on clinical phases I and II. All trials conducted within DKTK can be found in the trial registry of the Clinical Communication Platform. Studies financed within the Joint Funding Program are listed here.
Selection of Current DKTK Studies
AMPLIFY NEOVAC (NOA-21)
PSMAxCD3 Immuntherapie beim Prostatakarzinom (NCT04104607)
TOP-ART (NCT PMO-1603)